PCOS Officially Renamed to PMOS After Global Expert Consensus: Lancet
Australia: A major global consensus published in The Lancet has proposed renaming polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS), marking a significant shift in the understanding and classification of one of the most common endocrine disorders affecting women worldwide. The initiative emphasizes that the long-standing term PCOS is scientifically inaccurate, contributes to stigma, and fails to reflect the true multisystem nature of the condition.
The condition, which affects more than 170 million women globally, has traditionally been described in a way that implies the presence of ovarian cysts. However, experts now confirm that this is misleading, as such cysts are not a defining pathological feature. Instead, the disorder involves complex interactions across endocrine, metabolic, reproductive, dermatological, and psychological systems. The new term PMOS was developed to better capture this broader disease profile while improving clarity for patients, clinicians, researchers, and policymakers.
The consensus process was led by Prof Helena J Teede of Monash University and involved an unprecedented global collaboration. It included input from more than 14,360 individuals with PCOS and multidisciplinary health professionals across all regions of the world. The process combined iterative global surveys, modified Delphi methods, structured workshops, and implementation science approaches to ensure scientific rigor and broad representation.
Key concerns that drove the name change included:
- The term “polycystic ovary” incorrectly suggests ovarian cysts are central to the disease.
- The current name captures only reproductive features, ignoring endocrine and metabolic dysfunction.
- Misleading terminology contributes to delayed diagnosis and fragmented care pathways.
- Patients often report stigma and emotional distress linked to the terminology, especially in societies where fertility is socially sensitive.
- Inconsistent naming complicates disease classification, coding systems, and global research comparability.
- The existing terminology limits effective communication between patients and healthcare providers.
The consensus process identified key principles to guide the new name, ensuring that it would support clinical care, research, and global implementation. These included scientific accuracy, clarity of communication, avoidance of stigma, cultural and linguistic appropriateness, and feasibility of adoption across health systems.
After extensive evaluation, experts agreed that retaining the PCOS acronym or adopting a generic alternative would not adequately address these issues. Instead, a fully revised term was preferred. The selected name, polyendocrine metabolic ovarian syndrome, reflects the multisystem nature of the disorder by incorporating endocrine, metabolic, and ovarian components, while removing the misleading reference to cysts.
The final consensus highlights several important takeaways:
- PMOS more accurately reflects the endocrine and metabolic dysfunction underlying the condition.
- Removal of “cyst” corrects a long-standing scientific inaccuracy.
- The new terminology aims to reduce stigma and improve patient communication and understanding.
- The process was built on large-scale global participation, ensuring legitimacy and inclusivity.
- A structured implementation plan is already underway to support global transition.
To ensure smooth adoption, a detailed eight-stage implementation strategy has been developed. This includes academic publication and dissemination, development of multilingual educational resources, global communication campaigns, integration into electronic health records, alignment with research funding and policy systems, engagement with international classification bodies such as WHO, and updates to clinical guidelines. A three-year transition period has been proposed, during which the new terminology will be gradually integrated across healthcare systems, research frameworks, and educational platforms.
The authors note that implementation will be carefully monitored, with ongoing evaluation and refinement as scientific understanding evolves. Integration into international guidelines used across nearly 195 countries is also planned in upcoming updates.
The authors conclude that the transition from PCOS to PMOS represents a landmark shift in women’s health terminology. It aims to improve diagnostic accuracy, enhance research consistency, reduce stigma, and align clinical practice with current scientific understanding. Experts emphasize that this change is not merely semantic but foundational, with the potential to reshape global awareness, healthcare delivery, and patient outcomes for a condition affecting hundreds of millions of women worldwide.
Reference:
Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, D. A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Dokras, A., & Piltonen, T. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process. The Lancet. https://doi.org/10.1016/S0140-6736(26)00717-8
Next Story